Department of Neurology, Children's Hospital of Soochow University, Suzhou, China.
Medicine (Baltimore). 2022 Nov 11;101(45):e31408. doi: 10.1097/MD.0000000000031408.
Information on the effects of perampanel in Chinese children ≤12 years of age with refractory epilepsy is limited; thus, we conducted an observational study to assess the effectiveness, safety, and tolerability of adjunctive perampanel in this pediatric population. In this study, we reviewed the medical records of pediatric patients aged 4 to 12 years with refractory epilepsy who were admitted to Children's Hospital of Soochow University and prescribed perampanel between January 2020 and January 2021. Effectiveness of perampanel was measured by 50% responder rates, seizure-freedom rates, and retention rates for up to 48 weeks. Adverse events were monitored and recorded throughout the study. A total of 34 patients (male, n = 15) who exhibited refractory epilepsy were included in this study, and 64.71% of patients had focal-onset seizures combined with generalized epilepsy. The mean (± standard deviation) age of patients was 7.21 (± 2.12) years, with a mean (± standard deviation) age at seizure onset of 4.57 (± 2.59) years. After the addition of perampanel, the 50% responder rates at 4, 8, 12, 24, 36, and 48 weeks were 37.50% (12/32), 43.75% (14/32), 53.13% (17/32), 59.38% (19/32), 59.38% (19/32), and 62.07% (18/29). Two patients withdrew from perampanel treatment due to adverse events in the first 2 weeks. Adverse events were reported by 44.12% (15/34) of patients, and the retention rates at 36 and 48 weeks were 94.12% (32/34) and 85.29% (29/34), respectively. Overall, perampanel exhibited good effectiveness, safety, and tolerability in the treatment of pediatric patients (aged 4-12 years) with refractory epilepsy. These findings suggest that personalized treatment and better baseline seizure control may increase the responder rate and retention rate of perampanel.
在中国 4-12 岁难治性癫痫儿童中，有关吡仑帕奈的疗效信息有限；因此，我们开展了一项观察性研究，以评估吡仑帕奈在该儿科人群中的疗效、安全性和耐受性。在这项研究中，我们回顾性分析了 2020 年 1 月至 2021 年 1 月期间在苏州大学附属儿童医院就诊、并接受吡仑帕奈治疗的 4-12 岁难治性癫痫患儿的病历。通过 50%应答率、无癫痫发作率和最长 48 周的保留率来衡量吡仑帕奈的疗效。在整个研究过程中监测并记录不良反应事件。共有 34 名（男，n=15）难治性癫痫患儿纳入本研究，64.71%的患儿为局灶性发作伴全面性癫痫。患者的平均（±标准差）年龄为 7.21（±2.12）岁，平均（±标准差）起病年龄为 4.57（±2.59）岁。加用吡仑帕奈后，4、8、12、24、36 和 48 周的 50%应答率分别为 37.50%（12/32）、43.75%（14/32）、53.13%（17/32）、59.38%（19/32）、59.38%（19/32）和 62.07%（18/29）。两名患者在加用吡仑帕奈后前 2 周因不良反应退出。44.12%（15/34）的患者报告了不良反应事件，36 周和 48 周的保留率分别为 94.12%（32/34）和 85.29%（29/34）。总的来说，吡仑帕奈治疗 4-12 岁难治性癫痫儿童具有良好的疗效、安全性和耐受性。这些发现表明，个体化治疗和更好的基线癫痫发作控制可能会提高吡仑帕奈的应答率和保留率。
